Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 722.8 USD -0.12% Market Closed
Market Cap: 76B USD

During the last 3 months Regeneron Pharmaceuticals Inc insiders have not bought any shares, and sold 1.3m USD worth of shares. The stock price has increased by 26% over this period (open performance analysis).

The last transaction was made on Nov 20, 2025 by Bassler Bonnie L , who sold 570k USD worth of REGN shares.

Last Transactions:
Bassler Bonnie L
$-570k
Pitofsky Jason
$-280.8k
Poon Christine A
$-424.2k
Mccourt Marion
$-844.6k
Ryan Arthur F
$-3.1k
Mccourt Marion
$-1.1m
Mccourt Marion
$-1.2m
Ryan Arthur F
$-4.7k
Fenimore Christopher R.
$-274.7k
Bassler Bonnie L
$-884.5k
Poon Christine A
$-1.2m
Murphy Andrew J
$-62.7k
Stahl Neil
$-108.2k
Pitofsky Jason
$-521.1k
Bassler Bonnie L
$-842.9k
Mccourt Marion
$-1.2m
Ryan Arthur F
$-1.1k
Ryan Arthur F
$-1.1k
Larosa Joseph J
$-2m
Mccourt Marion
$-1.2m
Ryan Arthur F
$-3.1k
Bassler Bonnie L
$-802.9k
Brown Michael S
$-1.6m
Schleifer Leonard S
$-15.1m
Schleifer Leonard S
$-7.4m
Schleifer Leonard S
$-798.8k
Bassler Bonnie L
$-836.1k
Mccourt Marion
$-1.1m
Ryan Arthur F
$-2k
Brown Michael S
$-1.1m
Larosa Joseph J
$-1.9m
Schleifer Leonard S
$-22.2m
View All Transactions

During the last 3 months Regeneron Pharmaceuticals Inc insiders have not bought any shares, and sold 1.3m USD worth of shares. The stock price has increased by 26% over this period (open performance analysis).

The last transaction was made on Nov 20, 2025 by Bassler Bonnie L , who sold 570k USD worth of REGN shares.

Sold
0-3
months
1.3m USD
3
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Regeneron Pharmaceuticals Inc
Insider Trading Chart

Regeneron Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Regeneron Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Regeneron Pharmaceuticals Inc
Glance View

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

REGN Intrinsic Value
728.9 USD
Undervaluation 1%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top